Actavis announced that Namzaric (memantine HCl extended-release and donepezil HCl) capsules have launched for the treatment of moderate to severe Alzheimer’s disease in patients stabilized on memantine HCl and donepezil HCl.
Namzaric combines memantine HCl, a NMDA receptor antagonist, and donepezil HCl, an acetylcholinesterase inhibitor. Memantine is presumed to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive NMDA receptor antagonist which bind preferentially to the NMDA receptor-operated cation channels. Donepezil is presumed to exert its therapeutic effect by enhancing cholinergic function through increasing the concentration of acetylcholine in the central nervous system through reversible inhibition of its hydrolysis by acetylcholinesterase.
Namzaric is available as 14mg/10mg and 28mg/10mg strength capsules in 30- and 90-count bottles.
For more information call (800) 678-1605 or visit Namzaric.com.
This article originally appeared on MPR